

Special Issue

PET and SPECT Imaging for the Diagnosis of Neurodegenerative Diseases

Message from the Guest Editors

Neurodegenerative diseases are the leading cause of physical and cognitive decline affecting 15% of the population worldwide with cases of patients rising every year, with Alzheimer's disease, Parkinson's disease, and multiple sclerosis being the most ubiquitous diseases amongst the populations, to mention some examples. The biggest clinical challenge that we face is the early diagnoses of these disorders and is linked to the fact that the etiology of these disorders is still widely debatable. Positron emission tomography offers a great advantage over other imaging techniques due to its exceptional sensitivity and great specificity and has helped in recent years to shine some light over the questions posed by these maladies. There is a large variety of radioisotopes and biomarkers, and this is the reason why this Special Issue will welcome original research/review articles that highlight the research on the development of new tracers for the diagnosis of neurological disorders as well as the validation of new biomarkers that can be used to diagnose or elucidate the mechanisms of these pathologies.

Guest Editors

Dr. Paulina Gonzalez

University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA

Dr. Carlo Colosimo

Department of Neurology, Santa Maria University Hospital, 05100 Terni, Italy

Deadline for manuscript submissions

closed (31 October 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/218584

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).